INSM
$143.93
Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally.
Intraday
Recent News
Artisan Small Cap Fund Sold Insmed (INSM) on Valuation Consideration
Artisan Partners, an investment management company, released its fourth-quarter 2025 investor letter for “Artisan Small Cap Fund”. A copy of the letter can be downloaded here. The Fund seeks to invest in companies that possess franchise characteristics, with strong earnings trajectories, and are trading at a discount to the estimated private market value. Despite strong results […]
Insmed Incorporated (INSM) Price Target Raised to $211 at BofA
Insmed Incorporated (NASDAQ:INSM) is among the 10 Stocks That Could Skyrocket in 2026. On February 20, BofA analyst Jason Zemansky raised the firm’s price target on Insmed Incorporated (NASDAQ:INSM) to $211 from $209 and maintained a Buy rating. Although much of the near-term earnings outcome had been pre-announced, BofA characterized the subsequent earnings call as […]
Investment Manager Bets Big on PTCT Stock, Adds 41,000 Shares, According to Recent SEC Filing
PTC Therapeutics develops therapies for rare diseases, with a portfolio spanning commercial products and investigational candidates.
Is It Time To Reassess Insmed (INSM) After A 92% One Year Surge?
If you are wondering whether Insmed at US$146.32 is starting to look stretched or still offers value, you are not alone. This article focuses on what the current price might mean for potential investors. The stock has pulled back with an 8.0% decline over the last 7 days and a 6.7% decline over the last month. However, the share price is still up 91.8% over the past year and has a very large 3 year return. Recent news around Insmed has mainly centered on its position in the pharmaceuticals...
Assessing Insmed (INSM) Valuation After Recent Share Price Weakness And Brensocatib Launch Expectations
Insmed (INSM) has drawn fresh attention after recent trading left the stock with mixed returns, including a decline of about 5% over the past month and a drop of roughly 28% over the past 3 months. See our latest analysis for Insmed. At a share price of US$149.33, Insmed has seen short term pressure, with a 7 day share price return of around 6% decline and a 3 month share price return of about 28% decline. However, its 1 year total shareholder return of roughly 96% and very large 3 year total...